Skip to main content
Premium Trial:

Request an Annual Quote

Migenix Licenses GenomeQuest's Sequence Searcher

NEW YORK (GenomeWeb News) — GenomeQuest said today it is licensing its sequence search technology to Migenix, a Vancouver, BC-based drug developer. 
 
The company, formerly known as Gene-IT, said Migenix will use its GenomeQuest product in its clinical programs, which include drug candidates for hepatitis C, catheter-related infections, and dermatological diseases.
 
GenomeQuest said its application is used by biologists evaluating gene sequences and by patent lawyers who are considering issues of patentability of certain sequences.
 
The technology comprises close to 50 million patented sequences, the company said.
 
Financial terms of the agreement were not released.
 
Gene-IT said last week it has changed its name to GenomeQuest.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.